I found some additional material on the recent Eltoprazine trial that would seem to suggest that combination therapy with Eltoprazine and several other drugs has been investigated/studied already. I'm not familiar with all of these other drugs, so I'll try to do more research on them to see what the indications are and how Eltoprazine might tie in. The last paragraph (0052) seems to tie it all together in a list of possible indications. You'll have to forgive the legalese and "patent-speak" in these paragraphs.
For additional background, the co-inventors on the patent this was pulled from are Emer Leahy (president and CEO of Psychogenics) and Bavani Shankar (formerly VP at Psychogenics, now director of BD at AstraZeneca).
[0038] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one anticonvulsant. In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with primidone. In yet another embodiment, eltoprazine and/or a related compound(s) IS administered in combination with zonisamide.
[0039] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one mGluR5 antagonist. In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with AFQ056.
[0040] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one L-type calcium channel blocker. In other embodiments, eltoprazine and/or a related compound(s) is administered in combination with isradipine, nimodapine, or nilvadipine.
[0041] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one NMDA receptor antagonist. In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with remacemide. In yet another embodiment, eltoprazine and/or a related compound(s) is administered in combination with amantadine.
[0042] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one NMDA 2B receptor antagonist.
[0043] In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with Ro 25-6981.
[0044] In yet another embodiment, eltoprazine and/or a related compound(s) is administered in combination with EVT-101 or EVT-103.
[0045] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one adenosine A2a receptor antagonist. In another embodiment,
[0046] eltoprazine and/or a related compound(s) is administered in combination with KW-6002 (istradefylline). In a further embodiment, eltoprazine and/or a related compound(s) is
administered in combination with SCH420814 (preladenant).
[0047] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one alpha-2 adrenergic receptor antagonist. In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with JPl 730 (fipamezole). In a further embodiment, eltoprazine and/or a related compound(s) is administered in combination with idazoxan. In yet another embodiment, eltoprazine and/or a related compound(s) is administered in combination with SYN-115 (4-Hydroxy-N-[4-methoxy-7-(4- morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide, Synosia Therapeutics).
[0048] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one 4 hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor. In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with SYN-118, Synosia Therapeutics).
[0049] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one MAO-B inhibitor. In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with safinamide, rasagiline, selegiline, or ladostigil.
[0050] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one nicotinic acetylcholine receptor (nAChR) modulator. nAChR modulators include any compound that modulate the effect of the nAChR, including but not limited to nAChR selective or non-selective agonists, selective or non-selective partial agonists, competitive and non-competitive antagonists. In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with nicotine, acetylcholine, choline, epibatidine, lobeline, varenicline, or sazetidine-A.
[0051] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one phosphodiesterase (PDE) inhibitors, including at least PDE4
inhibitors and/or PDE2 inhibitors. In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with ronomilast.
[0052] In one embodiment, the invention is not used for prevention, attenuation, and/or treatment of the associated cognitive impairment in PD. In another embodiment, the invention is not used for prevention, attenuation, and/or treatment of any one or more of the following:
Alzheimer's disease, Huntington's disease, Cushing's syndrome, Lewy body disease, multiple sclerosis, stroke, addictive disorders, pervasive development disorder, Fragile X syndrome, anxiety disorders, Prader-Willi Syndrome, schizophrenia, bipolar disorder, depressive disorders, vascular dementia, mild cognitive impairment, dementia, or delirium. In an alternative embodiment, the invention may be used for prevention, attenuation, and/or treatment of one or more of these disorders.
For additional background, the co-inventors on the patent this was pulled from are Emer Leahy (president and CEO of Psychogenics) and Bavani Shankar (formerly VP at Psychogenics, now director of BD at AstraZeneca).
[0038] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one anticonvulsant. In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with primidone. In yet another embodiment, eltoprazine and/or a related compound(s) IS administered in combination with zonisamide.
[0039] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one mGluR5 antagonist. In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with AFQ056.
[0040] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one L-type calcium channel blocker. In other embodiments, eltoprazine and/or a related compound(s) is administered in combination with isradipine, nimodapine, or nilvadipine.
[0041] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one NMDA receptor antagonist. In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with remacemide. In yet another embodiment, eltoprazine and/or a related compound(s) is administered in combination with amantadine.
[0042] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one NMDA 2B receptor antagonist.
[0043] In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with Ro 25-6981.
[0044] In yet another embodiment, eltoprazine and/or a related compound(s) is administered in combination with EVT-101 or EVT-103.
[0045] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one adenosine A2a receptor antagonist. In another embodiment,
[0046] eltoprazine and/or a related compound(s) is administered in combination with KW-6002 (istradefylline). In a further embodiment, eltoprazine and/or a related compound(s) is
administered in combination with SCH420814 (preladenant).
[0047] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one alpha-2 adrenergic receptor antagonist. In another embodiment, eltoprazine and/or a related compound(s) is administered in combination with JPl 730 (fipamezole). In a further embodiment, eltoprazine and/or a related compound(s) is administered in combination with idazoxan. In yet another embodiment, eltoprazine and/or a related compound(s) is administered in combination with SYN-115 (4-Hydroxy-N-[4-methoxy-7-(4- morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide, Synosia Therapeutics).
[0048] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one 4 hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor. In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with SYN-118, Synosia Therapeutics).
[0049] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one MAO-B inhibitor. In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with safinamide, rasagiline, selegiline, or ladostigil.
[0050] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one nicotinic acetylcholine receptor (nAChR) modulator. nAChR modulators include any compound that modulate the effect of the nAChR, including but not limited to nAChR selective or non-selective agonists, selective or non-selective partial agonists, competitive and non-competitive antagonists. In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with nicotine, acetylcholine, choline, epibatidine, lobeline, varenicline, or sazetidine-A.
[0051] In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with at least one phosphodiesterase (PDE) inhibitors, including at least PDE4
inhibitors and/or PDE2 inhibitors. In one embodiment, eltoprazine and/or a related compound(s) is administered in combination with ronomilast.
[0052] In one embodiment, the invention is not used for prevention, attenuation, and/or treatment of the associated cognitive impairment in PD. In another embodiment, the invention is not used for prevention, attenuation, and/or treatment of any one or more of the following:
Alzheimer's disease, Huntington's disease, Cushing's syndrome, Lewy body disease, multiple sclerosis, stroke, addictive disorders, pervasive development disorder, Fragile X syndrome, anxiety disorders, Prader-Willi Syndrome, schizophrenia, bipolar disorder, depressive disorders, vascular dementia, mild cognitive impairment, dementia, or delirium. In an alternative embodiment, the invention may be used for prevention, attenuation, and/or treatment of one or more of these disorders.
